1606 related articles for article (PubMed ID: 11353048)
1. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
[TBL] [Abstract][Full Text] [Related]
2. P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus.
Schneider PM; Stoeltzing O; Roth JA; Hoelscher AH; Wegerer S; Mizumoto S; Becker K; Dittler HJ; Fink U; Siewert JR
Clin Cancer Res; 2000 Aug; 6(8):3153-8. PubMed ID: 10955797
[TBL] [Abstract][Full Text] [Related]
3. High-grade dysplasia and superficial adenocarcinoma in Barrett's esophagus: histological mapping and expression of p53, p21 and Bcl-2 oncoproteins.
Chatelain D; Fléjou JF
Virchows Arch; 2003 Jan; 442(1):18-24. PubMed ID: 12536310
[TBL] [Abstract][Full Text] [Related]
4. p53 in esophageal adenocarcinoma: a critical reassessment of mutation frequency and identification of 72Arg as the dominant allele.
Chung SM; Kao J; Hyjek E; Chen YT
Int J Oncol; 2007 Dec; 31(6):1351-5. PubMed ID: 17982662
[TBL] [Abstract][Full Text] [Related]
5. Molecular genetic analysis of surveillance biopsy samples from Barrett's mucosa--significance of sampling.
Werther M; Saure C; Pahl R; Schorr F; Rüschoff J; Alles JU; Heinmöller E
Pathol Res Pract; 2008; 204(5):285-94. PubMed ID: 18337019
[TBL] [Abstract][Full Text] [Related]
6. Nuclear accumulation of beta-catenin is a common and early event during neoplastic progression of Barrett esophagus.
Bian YS; Osterheld MC; Bosman FT; Fontolliet C; Benhattar J
Am J Clin Pathol; 2000 Oct; 114(4):583-90. PubMed ID: 11026105
[TBL] [Abstract][Full Text] [Related]
7. Accumulation of p53 protein in normal, dysplastic, and neoplastic Barrett's oesophagus.
Krishnadath KK; Tilanus HW; van Blankenstein M; Bosman FT; Mulder AH
J Pathol; 1995 Feb; 175(2):175-80. PubMed ID: 7738712
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic significance of nuclear p53 expression in the surveillance of Barrett's esophagus--a longitudinal study.
Klump B; Hsieh CJ; Holzmann K; Borchard F; Gaco V; Greschniok A; Eckardt VF; Bettendorf U; Gregor M; Porschen R
Z Gastroenterol; 1999 Oct; 37(10):1005-11. PubMed ID: 10549095
[TBL] [Abstract][Full Text] [Related]
9. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
[TBL] [Abstract][Full Text] [Related]
10. p53 gene mutations in Barrett's epithelium and esophageal cancer.
Casson AG; Mukhopadhyay T; Cleary KR; Ro JY; Levin B; Roth JA
Cancer Res; 1991 Aug; 51(16):4495-9. PubMed ID: 1868473
[TBL] [Abstract][Full Text] [Related]
11. Suppression of apoptosis does not foster neoplastic growth in Barrett's esophagus.
Soslow RA; Remotti H; Baergen RN; Altorki NK
Mod Pathol; 1999 Mar; 12(3):239-50. PubMed ID: 10102608
[TBL] [Abstract][Full Text] [Related]
12. p53-mutant clones and field effects in Barrett's esophagus.
Prevo LJ; Sanchez CA; Galipeau PC; Reid BJ
Cancer Res; 1999 Oct; 59(19):4784-7. PubMed ID: 10519384
[TBL] [Abstract][Full Text] [Related]
13. p53 immunoreactivity in Barrett's metaplasia, dysplasia, and adenocarcinoma--a case report.
Kimura H; Konishi K; Kaji M; Maeda K; Yabushita K; Miwa A
Hepatogastroenterology; 2001; 48(42):1662-4. PubMed ID: 11813596
[TBL] [Abstract][Full Text] [Related]
14. K-ras point mutations are rare events in premalignant forms of Barrett's oesophagus.
Trautmann B; Wittekind C; Strobel D; Meixner H; Keymling J; Gossner L; Ell C; Hahn EG
Eur J Gastroenterol Hepatol; 1996 Aug; 8(8):799-804. PubMed ID: 8864678
[TBL] [Abstract][Full Text] [Related]
15. Molecular evaluation of ablative therapy of Barrett's oesophagus.
Hage M; Siersema PD; Vissers KJ; Steyerberg EW; Haringsma J; Kuipers EJ; van Dekken H
J Pathol; 2005 Jan; 205(1):57-64. PubMed ID: 15586364
[TBL] [Abstract][Full Text] [Related]
16. p53 is frequently mutated in Barrett's metaplasia of the intestinal type.
Campomenosi P; Conio M; Bogliolo M; Urbini S; Assereto P; Aprile A; Monti P; Aste H; Lapertosa G; Inga A; Abbondandolo A; Fronza G
Cancer Epidemiol Biomarkers Prev; 1996 Jul; 5(7):559-65. PubMed ID: 8827361
[TBL] [Abstract][Full Text] [Related]
17. Detection of Barrett's adenocarcinoma of the gastric cardia with sucrase isomaltase and p53.
Iannettoni MD; Lee SS; Bonnell MR; Sell TL; Whyte RI; Orringer MB; Beer DG
Ann Thorac Surg; 1996 Nov; 62(5):1460-5; discussion 1465-6. PubMed ID: 8893584
[TBL] [Abstract][Full Text] [Related]
18. Apoptosis and cell proliferation in the metaplasia-dysplasia-carcinoma-sequence of Barrett's esophagus.
Halm U; Tannapfel A; Breitung B; Breidert M; Wittekind CW; Mössner J
Hepatogastroenterology; 2000; 47(34):962-6. PubMed ID: 11020858
[TBL] [Abstract][Full Text] [Related]
19. [Overexpression of protein p53 and Barrett esophagus. A frequent and early event in the course of carcinogenesis].
Fléjou JF; Volant A; Diebold MD; Sagan C; Vissuzaine C; Croué A; Robaszkiewicz M; Potet F
Gastroenterol Clin Biol; 1995 May; 19(5):475-81. PubMed ID: 7589998
[TBL] [Abstract][Full Text] [Related]
20. Survivin, a potential biomarker in the development of Barrett's adenocarcinoma.
Vallböhmer D; Peters JH; Oh D; Kuramochi H; Shimizu D; Demeester SR; Hagen JA; Chandrasoma PT; Danenberg KD; DeMeester TR; Danenberg P
Surgery; 2005 Oct; 138(4):701-6; discussion 706-7. PubMed ID: 16269299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
